We have demonstrated that a PARP inhibitor, which can effectively restore tamoxifen sensitivity in tamoxifen—resistant ER+ breast cancer cells, might be a potentially promising addition to tamoxifen as a combination regimen for patients carrying the CTSO V/ZNF423 W SNP genotype. Here, ZNF423 is linked to breast carcinoma.